Cargando…

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

The astonishing clinical success of CD19 chimeric antigen receptor (CAR) T-cell therapy has led to the approval of two second generation chimeric antigen receptors (CARs) for acute lymphoblastic leukemia (ALL) andnon-Hodgkin lymphoma (NHL). The focus of the field is now on emulating these successes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kueberuwa, Gray, Zheng, Weiming, Kalaitsidou, Milena, Gilham, David E., Hawkins, Robert E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MyJove Corporation 2018
Materias:	Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235544/ https://www.ncbi.nlm.nih.gov/pubmed/30394400 http://dx.doi.org/10.3791/58492

Ejemplares similares

CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity
por: Kueberuwa, Gray, et al.
Publicado: (2017)

Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer
por: Owens, Gemma L., et al.
Publicado: (2018)

Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies
por: Shohdy, Kyrillus S., et al.
Publicado: (2023)

Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model
por: Ranoa, Diana Rose E, et al.
Publicado: (2023)

Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China
por: Ying, Zhitao, et al.
Publicado: (2020)

Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes
por: Kalaitsidou, Milena, et al.
Publicado: (2023)

Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model
por: Klampatsa, Astero, et al.
Publicado: (2020)

Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma
por: Monfrini, Chiara, et al.
Publicado: (2022)

CCR7(+) selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo
por: Kueberuwa, Gray, et al.
Publicado: (2017)

Transgenic T-cell receptor immunotherapy for cancer: building on clinical success
por: Oppermans, Natasha, et al.
Publicado: (2020)

Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B‐cell lymphoma
por: Ma, Xiao‐bo, et al.
Publicado: (2018)

IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
por: Shi, Hongtai, et al.
Publicado: (2023)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
por: Su, Lihe, et al.
Publicado: (2022)

CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma
por: Quintás-Cardama, Alfonso
Publicado: (2018)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
por: Anker, Jonathan F., et al.
Publicado: (2018)

Filgrastim associations with CAR T‐cell therapy
por: Gaut, Daria, et al.
Publicado: (2020)

Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
por: Georgiev, Peter, et al.
Publicado: (2022)

Single-Cell Landscape of Mouse Islet Allograft and Syngeneic Graft
por: Chen, Pengfei, et al.
Publicado: (2022)

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma
por: Yan, Lingzhi, et al.
Publicado: (2020)

Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells
por: Feng, Jia, et al.
Publicado: (2022)

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2021)

Pre‐diagnostic blood immune markers, incidence and progression of B‐cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses
por: Vermeulen, Roel, et al.
Publicado: (2018)

Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
por: Itzhaki, Orit, et al.
Publicado: (2020)

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
por: Sang, Wei, et al.
Publicado: (2020)

Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients
por: Hu, Maogui, et al.
Publicado: (2021)

CD70‐targeting CAR‐T cells have potential activity against CD19‐negative B‐cell Lymphoma
por: Deng, Wenhai, et al.
Publicado: (2021)

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA
por: Luo, Wenjing, et al.
Publicado: (2023)

S230: CD22 CAR T CELL THERAPY IS SAFE AND EFFECTIVE IN PATIENTS WITH LARGE B CELL LYMPHOMA WHO HAVE RELAPSED AFTER CD19 CAR T CELL THERAPY.
por: Frank, Matthew J., et al.
Publicado: (2023)

CAR T-Cell Therapy for Large B-Cell Lymphoma
por: Alencar, Maritza C.
Publicado: (2019)

CAR-T Cell Therapy in Large B Cell Lymphoma
por: Testa, Ugo, et al.
Publicado: (2023)

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
por: Song, Fengmei, et al.
Publicado: (2023)

Anti-CD19 CAR T-Cell Therapy for Adult Patients With Refractory Large B-Cell Lymphoma
por: McDermott, Kathleen, et al.
Publicado: (2019)

CD8(+) T cell concentration determines their efficiency in killing cognate antigen–expressing syngeneic mammalian cells in vitro and in mouse tissues
por: Budhu, Sadna, et al.
Publicado: (2010)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
por: Xue, YuanBo, et al.
Publicado: (2021)

Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo
por: Yin, Yuzhen, et al.
Publicado: (2022)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy
por: Sheih, Alyssa, et al.
Publicado: (2020)

Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia
por: Sánchez Martínez, Diego, et al.
Publicado: (2022)

CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models
por: Timpanaro, Andrea, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c7vqm7j6n2ra2gr6htbm7ra5dp